β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.

@article{Huang2016asaroneAL,
  title={β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.},
  author={Liping Huang and Minzhen Deng and Yuping He and Shiyao Lu and Ruanxin Ma and Yong-qi Fang},
  journal={Clinical and experimental pharmacology & physiology},
  year={2016},
  volume={43 6},
  pages={
          634-43
        }
}
Levodopa (L-dopa) is widely considered as one of the most effective drug constituents in the treatment of Parkinson's disease (PD), but the blood-brain barrier (BBB) permeability of L-dopa is <5%, which causes low efficacy. Neuroprotective effects of β-asarone on 6-hydroxydopamine (6-OHDA)-induced PD rats were demonstrated by our previous studies. Co-administration of β-asarone and L-dopa has not been explored until being investigated on PD rats in this study. PD rats were divided into four… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS